Somatostatin Receptors 3, 4 and 5 Play Important Roles in Gallbladder Cancer

  • Guo, Run-Sheng (Department of General Surgery, Jiading Central Hospital) ;
  • Shi, Pei-Dong (Department of General Surgery, Jiading Central Hospital) ;
  • Zhou, Jie (Department of Ultrasound, Jiading Central Hospital) ;
  • Chen, Yue-Yu (Department of General Surgery, Jiading Central Hospital)
  • Published : 2013.07.30


Expression changes of somatostatin receptor subtypes (SSTRs) including SSTR1, SSTR2, SSTR3, SSTR4 and SSTR5 in the development of gallbladder cancer were assessed with attention to relationships with clinical pathological characteristics. SSTRs in 29 gallbladder cancer and 25 normal gallbladder tissue specimens were examined by immunohistochemical staining. Differences between SSTRs expressions and clinical pathological parameters were analyzed by chi-square test. The five subtypes of SSTR were all expressed in gallbladder cancer tissues and SSTR3 presented the highest expression. SSTR5 expression was increased significantly in gallbladder cancer (P<0.05) compared with that in normal gallbladder tissue. SSTR3 expression in highly and moderately differentiated gallbladder cancer was significantly higher than that in poorly differentiated lesions (P<0.05). SSTR4 expression was lower in gallbladder cancer with lymph node metastasis than that in gallbladder cancer without lymph node metastasis (P<0.05). Therfore, these results indicated that SSRT5, SSTR3 and SSTR4 may play important roles in the formation and development of gallbladder cancer.


Gallbladder cancer;somatostatin (SST);somatostain receptor (SSTR)


  1. Barbare JC, Bouche O, Bonnetain F, et al (2009). Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer, 45, 1788-97.
  2. Behr TM, Behe MP (2002). Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies. Semin Nucl Med, 32, 97-109.
  3. Bell GI, Yasuda K, Kong H, et al (1995). Molecular biology of somatostatin receptors. Ciba Found Symp, 190, 65-79; discussion 80-8.
  4. Bousquet C, Guillermet J, Vernejoul F, et al (2004). Somatostatin receptors and regulation of cell proliferation. Dig Liver Dis, 36, S2-7.
  5. Buscail L, Vernejoul F, Faure P, et al (2002). [Regulation of cell proliferation by somatostatin]. Ann Endocrinol (Paris), 63, 2S13-8.
  6. Chopra A (2004). 99mTc-Tricarbonyl-K-H-K-H-cholecystokinin 8. in 'Molecular Imaging and Contrast Agent Database (MICAD)': Bethesda (MD).
  7. de Aretxabala X, Losada H, Mora J, et al (2004). [Neoadjuvant chemoradiotherapy in gallbladder cancer]. Rev Med Chil, 132, 51-7.
  8. de Sa SV, Correa-Giannella ML, Machado MC, et al (2006). Somatostatin receptor subtype 5 (SSTR5) mRNA expression is related to histopathological features of cell proliferation in insulinomas. Endocr Relat Cancer, 13, 69-78.
  9. DeYoung JL, Lien EL (1984). A long-acting injectable dosage form for a somatastatin analog. J Parenter Sci Technol, 38, 234-6.
  10. Fiebiger WC, Scheithauer W, Traub T, et al (2002). Absence of therapeutic efficacy of the somatostatin analogue lanreotide in advanced primary hepatic cholangiocellular cancer and adenocarcinoma of the gallbladder despite in vivo somatostatin-receptor expression. Scand J Gastroenterol, 37, 222-5.
  11. Garske U, Sandstrom M, Johansson S, et al (2012). Minor changes in effective half-life during fractionated 177Lu-octreotate therapy. Acta Oncol, 51, 86-96.
  12. Gong W, Qin YY, Li SG, et al (2010). [Somatostatin enhanced anti-tumor effect of doxorubicin on gallbladder cancer cells through the regulation of intracellular drug concentration]. Zhonghua Yi Xue Za Zhi, 90, 2718-22.
  13. Gottsmann M, Landgraf R, Londong W, Werder K (1975). [Influence of somatastatin on oral glucose tolerance in autonomous hypersecretion of growth hormone, prolactin or insulin (author's transl)]. Klin Wochenschr, 53, 1161-6.
  14. Hall GH, Turnbull LW, Richmond I, et al (2002). Localisation of somatostatin and somatostatin receptors in benign and malignant ovarian tumours. Br J Cancer, 87, 86-90.
  15. Harada K, Sato Y, Ikeda H, et al (2012). Clinicopathologic study of mixed adenoneuroendocrine carcinomas of hepatobiliary organs. Virchows Arch, 460, 281-9.
  16. Hashimoto K, Masumori N, Tanaka T, et al (2013). Zoledronic acid but not somatostatin analogs exerts anti-tumor effects in a model of murine prostatic neuroendocrine carcinoma of the development of castration-resistant prostate cancer. Prostate, 73, 500-11.
  17. Hofsli E (2002). [The somatostatin receptor family--a window against new diagnosis and therapy of cancer]. Tidsskr Nor Laegeforen, 122, 487-91.
  18. Hoyer D, Bell GI, Berelowitz M, et al (1995). Classification and nomenclature of somatostatin receptors. Trends Pharmacol Sci, 16, 86-8.
  19. Kaczmarek P, Singh V, Cashen DE, et al (2010). Somatostatin receptor subtypes 2 and 5 mediate inhibition of egg yolk-induced gall bladder emptying in mice. Neurogastroenterol Motil, 22, 204-9, e66.
  20. Kailey B, van de Bunt M, Cheley S, et al (2012). SSTR2 is the functionally dominant somatostatin receptor in human pancreatic beta- and alpha-cells. Am J Physiol Endocrinol Metab, 303, E1107-16.
  21. Kim K, Chie EK, Jang JY, et al (2012). Postoperative chemoradiotherapy for gallbladder cancer. Strahlenther Onkol, 188, 388-92.
  22. Kouroumalis E, Skordilis P, Thermos K, et al (1998). Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut, 42, 442-7.
  23. Kuriyama I, Miyazaki A, Tsuda Y, et al (2013). Inhibitory effect of novel somatostatin peptide analogues on human cancer cell growth based on the selective inhibition of DNA polymerase beta. Bioorg Med Chem, 21, 403-11.
  24. Lamberts SW, van der Lely AJ, Hofland LJ (2002). New somatostatin analogs: will they fulfil old promises? Eur J Endocrinol, 146, 701-5.
  25. Moss CE, Marsh WJ, Parker HE, et al (2012). Somatostatin receptor 5 and cannabinoid receptor 1 activation inhibit secretion of glucose-dependent insulinotropic polypeptide from intestinal K cells in rodents. Diabetologia, 55, 3094-103.
  26. Olias G, Viollet C, Kusserow H, et al (2004). Regulation and function of somatostatin receptors. J Neurochem, 89, 1057-91.
  27. Patel YC, Greenwood M, Kent G, et al (1993). Multiple gene transcripts of the somatostatin receptor SSTR2: tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun, 192, 288-94.
  28. Patel YC (1999). Somatostatin and its receptor family. Front Neuroendocrinol, 20, 157-98.
  29. Peverelli E, Busnelli M, Vitali E, et al (2012). Specific roles of Gi protein family members revealed by dissecting somatostatin receptor 5 (SST5) coupling in human pituitary cells. J Cell Sci, 126, 638-44.
  30. Pisarek H, Stepien T, Kubiak R, et al (2009). Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Res, 2, 1.
  31. Quan ZW, Yang Y, Li JY, et al (2010). The mechanisms of somatostatin induced enhanced chemosensitivity of gallbladder cancer cell line to doxorubicin: cell cycle modulation plus target enzyme up-regulation. Biomed Pharmacother, 64, 451-7.
  32. Reisine T, Bell GI (1995). Molecular biology of somatostatin receptors. Endocr Rev, 16, 427-42.
  33. Reubi JC, Schaer JC, Markwalder R, et al (1997). Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance. Yale J Biol Med, 70, 471-9.
  34. Ruscica M, Arvigo M, Gatto F, et al (2010). Regulation of prostate cancer cell proliferation by somatostatin receptor activation. Mol Cell Endocrinol, 315, 254-62.
  35. Schulz S, Schulz S, Schmitt J, et al (1998). Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtypespecific antibodies. Clin Cancer Res, 4, 2047-52.
  36. Seitz S, Buchholz S, Schally AV, et al (2013). Targeting triple-negative breast cancer through the somatostatin receptor with the new cytotoxic somatostatin analogue AN-162 [AEZS-124]. Anticancer Drugs, 24, 150-7.
  37. Songgang L, Jiyu L, Gongwei, et al (2009). Somatostatin enhances the chemosensitivity of GBC-SD cell line to doxorubicin through arresting the cell cycle to S phase rather than through the P53/Bax-depended apoptosis way in vitro. Hepatogastroenterology, 56, 1253-60.
  38. Susini C, Buscail L (2006). Rationale for the use of somatostatin analogs as antitumor agents. Ann Oncol, 17, 1733-42.
  39. Toumpanakis C, Caplin ME (2013). Update on the role of somatostatin analogs for the treatment of patients with gastroenteropancreatic neuroendocrine tumors. Semin Oncol, 40, 56-68.
  40. Treglia G, Lococo F, Petrone G, et al (2013). Pulmonary Neuroendocrine Tumor Incidentally Detected by 18F-CH PET/CT. Clin Nucl Med, 38, 196-9.
  41. Valsecchi ME, Coronel M, Intenzo CM, et al (2013). Somatostatin receptor scintigraphy in patients with metastatic uveal melanoma. Melanoma Res, 23, 33-9.

Cited by

  1. High Frequency of TP53 but not K-ras Gene Mutations in Bolivian Patients with Gallbladder Cancer vol.15, pp.13, 2014,
  2. Research update for articles published in EJCI in 2012 vol.44, pp.10, 2014,
  3. Down-regulation of pancreatic and duodenal homeobox-1 by somatostatin receptor subtype 5: a novel mechanism for inhibition of cellular proliferation and insulin secretion by somatostatin vol.5, pp.1664-042X, 2014,
  4. Somatostatin Receptor 2 and 5 Expressions in Gastroenteropancreatic Neuroendocrine Tumors in Turkey vol.16, pp.10, 2015,
  5. The transcriptome landscape of the carcinogenic treatment response in the blind mole rat: insights into cancer resistance mechanisms vol.20, pp.1, 2019,